| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| Targets |
The primary targets of 2-Hydroxy-4-methoxybenzoic acid are not fully characterized, but it is known to inhibit mushroom tyrosinase in a non-competitive manner. Tyrosinase is a key enzyme in melanin biosynthesis. The compound's anti-diabetic, hypolipidemic, hepatoprotective, and anti-snake venom activities suggest it may interact with multiple pathways involved in metabolism, inflammation, and oxidative stress.
|
|---|---|
| ln Vitro |
In vitro, 2-Hydroxy-4-methoxybenzoic acid inhibits the diphenolase activity of mushroom tyrosinase. It also exhibits anti-diabetic, hypolipidemic, hepatoprotective, and anti-snake venom activities. These activities suggest it has potential as a therapeutic agent for metabolic and liver diseases. Its mechanism of action may involve antioxidant and anti-inflammatory effects, but further studies are needed to elucidate its specific targets.
|
| ln Vivo |
In vivo efficacy data for 2-Hydroxy-4-methoxybenzoic acid are not extensively detailed. Its reported activities suggest potential in animal models of diabetes, hyperlipidemia, and liver injury. However, specific in vivo studies with this compound are not widely reported. It is intended for research use only.
|
| Enzyme Assay |
For tyrosinase inhibition assays, mushroom tyrosinase is incubated with varying concentrations of 2-Hydroxy-4-methoxybenzoic acid in a reaction buffer containing the substrate L-DOPA. The reaction is monitored by measuring the increase in absorbance at 475 nm due to the formation of dopachrome. The inhibition type (non-competitive) is determined by Lineweaver-Burk plot analysis.
|
| Cell Assay |
For cellular studies, cells such as hepatocytes or adipocytes are cultured in appropriate medium. 2-Hydroxy-4-methoxybenzoic acid is dissolved in DMSO and diluted in culture medium. Cells are treated with the compound, and various parameters are measured, including cell viability, glucose uptake, lipid accumulation, and inflammatory cytokine production. For mechanistic studies, signaling pathways like NF-κB and AMPK are analyzed by Western blot.
|
| Animal Protocol |
For in vivo efficacy studies, animal models of diabetes, hyperlipidemia, or liver injury could be used. 2-Hydroxy-4-methoxybenzoic acid would be formulated in vehicle and administered orally or intraperitoneally. Blood glucose, lipid profiles, and liver enzymes would be measured. Tissues would be collected for histopathological examination and analysis of oxidative stress markers.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 2-Hydroxy-4-methoxybenzoic acid are not extensively reported. As a small molecule with a molecular weight of 168.15, it is expected to have moderate oral bioavailability. Its metabolism likely involves conjugation and hepatic clearance. A comprehensive PK study would be needed to determine its half-life, Cmax, and AUC for any potential therapeutic development.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2-Hydroxy-4-methoxybenzoic acid are limited. No acute toxicity, organ-specific toxicity, or mutagenicity data have been reported. As with all research chemicals, appropriate safety precautions should be taken during handling.
|
| Additional Infomation |
4-Methoxysalicylic acid is a methoxybenzoic acid. It has been reported to be found in aconite, caperca, and other organisms with relevant data.
2-Hydroxy-4-methoxybenzoic acid (CAS 2237-36-7) is a non-competitive inhibitor of mushroom tyrosinase. It has the molecular formula C₈H₈O₄ and a molecular weight of 168.15. It exhibits anti-diabetic, hypolipidemic, hepatoprotective, and anti-snake venom activities and is strictly for research use. |
| Molecular Formula |
C8H8O4
|
|---|---|
| Molecular Weight |
168.1467
|
| Exact Mass |
168.042
|
| CAS # |
2237-36-7
|
| PubChem CID |
75231
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
328.7±27.0 °C at 760 mmHg
|
| Melting Point |
158-159 °C(lit.)
|
| Flash Point |
137.9±17.2 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.586
|
| LogP |
2.24
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
12
|
| Complexity |
168
|
| Defined Atom Stereocenter Count |
0
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~297.35 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9471 mL | 29.7354 mL | 59.4707 mL | |
| 5 mM | 1.1894 mL | 5.9471 mL | 11.8941 mL | |
| 10 mM | 0.5947 mL | 2.9735 mL | 5.9471 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
